Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer Sharon Worcester May 01, 2026

https://www.medscape.com/viewarticle/vepdegestrant-earns-fda-nod-esr1-mutated-breast-cancer-2026a1000e23 The FDA has approved vepdegestrant (Veppanu, Arvinas Operations) for the treatment of certain patients with ER-positive, HER2-negative advanced or metastatic breast cancer.